Literature DB >> 17308143

Indices of low-grade inflammation in polycystic ovary syndrome.

Evanthia Diamanti-Kandarakis1, Thomas Paterakis, Helen A Kandarakis.   

Abstract

Polycystic ovary syndrome (PCOS) is probably the most common endocrinopathy of reproductive age. PCOS represents a disorder that not only enhances the risk for type 2 diabetes (T2D) but is also associated with an increased number of cardiovascular risk factors known to facilitate atherogenesis. On the other hand, inflammation is thought to play an important role in the progression and development of complications of atherosclerosis. Evidence of low-grade chronic inflammation in PCOS is indicated by the presence of elevated C-reactive protein (CRP) levels, inflammatory cytokines (i.e., IL-6 and IL-18), and increased leucocyte count. CRP, a nonspecific marker of inflammation, has been proven to be one of the strongest predictors of the risk of cardiovascular events in patients with or without cardiovascular disease. The levels of the adhesion molecules (AM), sIVAM-1, sVCAM-1, and sE-selectin in serum reflect low-grade chronic inflammation of the endothelium and independently predict coronary heart disease (CHD) and T2D. In a recent study in a large number of PCOS women we demonstrated elevated levels of sIVAM-1 and sE-selectin and we further substantiated the existence of a low-grade chronic inflammatory process in PCOS. However, it remains to be assessed with long-term studies whether the early presence of markers of chronic inflammation in young women with this syndrome has clinical significance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308143     DOI: 10.1196/annals.1365.015

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Common Inflammatory Markers in Polycystic Ovary Syndrome (PCOS): A BMI (Body Mass Index)-Matched Case-Control Study.

Authors:  Sudhindra Mohan Bhattacharya; Atreyee Basu
Journal:  J Obstet Gynaecol India       Date:  2018-06-19

2.  Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.

Authors:  Melissa Pawelczak; Jamie Rosenthal; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-09-23       Impact factor: 1.814

3.  Interleukin 1 beta (IL-1β) promoter C [-511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome.

Authors:  Yuan Mu; Jingjing Liu; Binbin Wang; Qiaolian Wen; Jing Wang; Jinting Yan; Sirui Zhou; Xu Ma; Yunxia Cao
Journal:  Endocrine       Date:  2009-11-10       Impact factor: 3.633

4.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

Review 5.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

6.  A lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes.

Authors:  Barbara A Gower; Amy M Goss
Journal:  J Nutr       Date:  2014-12-03       Impact factor: 4.798

Review 7.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

8.  Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure.

Authors:  F Ermetici; A E Malavazos; S Corbetta; C Eller-Vainicher; S Cannavò; M M Corsi; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.